Castle Creek

Central Payments Closes $30 Million Growth Equity Raise

Retrieved on: 
Thursday, August 11, 2022
API, Castle Creek, Community development financial institution, CEO, Choice, CA, Technology, Investment, Science and technology in Asia, Community development, CBKC, Bank, Education, CDFI, FDIC, Office of the Supervising Architect for the U.S. Treasury, Solution, LinkedIn, Central bank, Cryptocurrency, Financial services

SIOUX FALLS, S.D., Aug. 11, 2022 /PRNewswire-PRWeb/ -- Central Payments, architect of the award-winning Open*CP Fintech API Marketplace℠ and the country's fastest growing prepaid card issuer*, announced today that it has completed a $30 million growth equity raise. Castle Creek Capital led the round with additional investment from Launchpad Capital. The transaction spins the banking-as-a-service leader out from Central Bank of Kansas City and further accelerates its rapid growth trajectory.

Key Points: 
  • SIOUX FALLS, S.D., Aug. 11, 2022 /PRNewswire-PRWeb/ -- Central Payments , architect of the award-winning Open*CP Fintech API Marketplace and the country's fastest growing prepaid card issuer*, announced today that it has completed a $30 million growth equity raise.
  • The transaction spins the banking-as-a-service leader out from Central Bank of Kansas City and further accelerates its rapid growth trajectory.
  • "Trent and his team at Central Payments saw this opportunity and executed on it before most knew what 'banking-as-a-service' meant."
  • Sorbe founded Central Payments in 2014 with Central Bank of Kansas City (CBKC), one of the country's leading Community Development Financial Institutions (CDFI).

Middlefield Banc Corp. and Liberty Bancshares, Inc. Announce Merger

Retrieved on: 
Thursday, May 26, 2022
Form, U.S. Securities and Exchange Commission, Bank, OTC Markets Group, George Orwell, Report, Director, Human, Risk, Private Securities Litigation Reform Act, SEC, Castle Creek, Annual report, II, John Martin Vorys, COVID-19, Sater, Board, Associate, Growth, Prospectus, GLOBE, Company, Keefe, Bruyette & Woods, Partnership, Board of directors, Security (finance), LPL, NASDAQ, Creek, ADA, Philosophy, Industry, Forward-looking statement, Plan, Technology, Person, CEO, Bookkeeping, Agreement

MIDDLEFIELD, Ohio and ADA, Ohio, May 26, 2022 (GLOBE NEWSWIRE) -- Middlefield Banc Corp. (“Middlefield”, or the “Company”) (NASDAQ: MBCN), the bank holding company for The Middlefield Banking Company, and Liberty Bancshares, Inc. (OTC Markets: LBSI) (“Liberty”), the holding company for Liberty National Bank, jointly announced today that they have entered into an Agreement and Plan of Reorganization (the “Agreement”).

Key Points: 
  • In addition, Mr. Zimmerly will become President of Middlefield Banc Corp. assuming Middlefield shareholders approve amendments to the Companys Regulations that separate the positions of President and CEO.
  • Middlefield Banc Corp., headquartered in Middlefield, Ohio, is the bank holding company of The Middlefield Banking Company with total assets of $1.32 billion at March 31, 2022.
  • Middlefield Banc Corp. shareholders, Liberty Bancshares, Inc. shareholders, and other investors are urged to read carefully the proxy statement/prospectus to be included in the Form S-4 registration statement, because the proxy statement/prospectus will contain important information about Middlefield Banc Corp., Liberty Bancshares, Inc., the proposed merger, the persons soliciting proxies for the proposed merger, their interests in the proposed merger, and related matters.
  • Copies of the documents filed with the SEC by Middlefield Banc Corp. are available free of charge on Middlefields website at www.middlefieldbank.bank .

Texas Community Bancshares, Inc. Announces Addition of Four New Board Members

Retrieved on: 
Thursday, February 24, 2022
Risk, Guaranty Federal Bancshares, Austin College, Piper Sandler Companies, Universal Technical Institute, Company, Bank, McWane, Addie, Board of directors, Board, Pastor, List of counseling topics, EFSC, Business, Pharmacist, City, Angelina College, BBA, Multimedia, MBA, Audit committee, Director, Certification, Economic development, Nasdaq, MPB, CFA, NASDAQ, Castle Creek, Financial compensation, View, Moses Austin, University, Quality, University of Chicago Booth School of Business, St. Paul Missionary Baptist Church, Community Bank, Executive Committee, Management, Pharmacy

MINEOLA, Texas, Feb. 24, 2022 /PRNewswire/ -- Texas Community Bancshares, Inc. (the "Company"), the holding company of Mineola Community Bank, S.S.B.

Key Points: 
  • MINEOLA, Texas, Feb. 24, 2022 /PRNewswire/ -- Texas Community Bancshares, Inc. (the "Company"), the holding company of Mineola Community Bank, S.S.B.
  • (the "Bank"), announced today the recent addition of four new members to the Boards of Directors of the Company and the Bank.
  • He currently serves on the Board for the Grand Saline Economic Development Corporation as well as the Grand Saline Hospital Board.
  • Texas Community Bancshares is the holding company for Mineola Community Bank, a Texas-chartered savings bank that operates six full-service offices in northeast Texas.

Castle Creek Biosciences Awarded FDA Orphan Products Development Grant to Support DeFi-RDEB, a Pivotal Phase 3 Study of FCX-007 Investigational Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Retrieved on: 
Thursday, October 21, 2021
Aurora, Paragon, Program, Solution, Children's Hospital, Orphan drug, Research, Fibroblast, COL7, Castle Creek, Regenerative medicine, Mayo Clinic, Twitter, Dell Children's Medical Center, Patient, Concha bullosa, Children's Hospital Colorado, FDA, Stanford University, Scar, COL7A1, Boston Medical Group, Dell, LLC, Principal, VII, Degenerative disease, Skin, Friction, Genetic disorder, Trauma, DEB, ClinicalTrials.gov, Pharmaceutical industry

EXTON, Pa., Oct. 21, 2021 /PRNewswire/ -- Castle Creek Biosciences, Inc., a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options, today announced that the U.S. Food & Drug Administration (FDA) Office of Orphan Products Development (OOPD) has awarded the company a $1.825 million research grant over four years (#1R01–FD007289-01). The grant supports a meaningful portion of the Phase 3 clinical development of dabocemagene autoficel (FCX-007, D-Fi), an investigational gene therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).

Key Points: 
  • The grant supports a meaningful portion of the Phase 3 clinical development of dabocemagene autoficel (FCX-007, D-Fi), an investigational gene therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
  • The Congressionally-funded Orphan Products Development Grants Program is designed to enhance the development of medical products for patients with rare diseases.
  • RDEB is a progressive, devastatingly painful and debilitating, rare genetic disorder, and one of the most chronic and severe forms of DEB.
  • Castle Creek Biosciences' dabocemagene autoficel (FCX-007, D-Fi) is being developed to address the deficiency of functional type VII collagen protein (COL7) in patients with dystrophic epidermolysis bullosa (DEB).

Castle Creek Biosciences Expands its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders through Research Collaboration with Mayo Clinic

Retrieved on: 
Wednesday, September 29, 2021
Paragon, OI, Scoliosis, Hyperextension (exercise), Chronic pain, RDEB, Skin, Castle Creek, Joint, CGMP, Hypotonia, EDS, FDA, Patient, Amelogenesis imperfecta, Degenerative disease, Twitter, LLC, Fragility, Ligamentous laxity, Connective tissue, Research, Mayo Clinic, Osteogenesis imperfecta, Mortal Kombat, Pharmaceutical industry

The research will be led by principal investigator David R. Deyle, M.D., a board-certified medical geneticist with the department of medical genetics at Mayo Clinic and a leader in the field of connective tissue disorders.

Key Points: 
  • The research will be led by principal investigator David R. Deyle, M.D., a board-certified medical geneticist with the department of medical genetics at Mayo Clinic and a leader in the field of connective tissue disorders.
  • "We are honored to be working with Dr. Deyle and his highly regarded research team at Mayo Clinic to identify and evaluate gene therapy candidates that hold promise for treating debilitating, rare connective tissue disorders with high unmet medical needs," said Matthew Gantz, president and chief executive officer of Castle Creek Biosciences.
  • For this research collaboration, Castle Creek will contribute its proficiency in rare diseases and gene therapy development and has licensed intellectual property related to OI and classical EDS from Mayo Clinic.
  • The company's proprietary autologous fibroblast platform potentially allows for the development ofpersonalized, targeted and redosable cell-based gene therapy product candidates formonogenic and chronic disorders.